HopeMed (Hmi115) is pissed at Absci (Abs-201) 8/30/2026
HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Prolactin the Cause of Hair Loss? ABS-201 the Cure?
Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community Finally, some real breakthroughs. A comparison of the two leading baldness treatments: PP405 versus ABS-201
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community ABS-201 KOL Seminar: Dr. Ralf Paus on Human Ex Vivo Hair Regrowth Data
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
Related Research
6 / 6 resultsresearch Recent approaches of antibody therapeutics in androgenetic alopecia
This review discusses the potential of therapeutic antibodies as an alternative treatment for androgenetic alopecia, highlighting the initial development stages and the need for further validation and optimization of targets like the prolactin receptor and Interleukin-6 receptor.
research Emerging pharmacotherapies for Androgenetic Alopecia
This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
research Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.
research The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research A Study on the Effectiveness and Safety of Herbal Extract Combination Compared to 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A Randomized, Double-blind, Controlled Trial
In this study, researchers reported that an herbal extract with dihydroquercetin glucoside, epigallocatechin gallate glucoside, zinc, and glycine showed similar effectiveness and safety to minoxidil in treating androgenetic alopecia over 24 weeks, with no significant differences in hair growth outcomes between the groups.
research A dietary supplement improves age-related dermatological changes. Observational, anecdotal, spontaneous study.
This study found that dietary supplementation with collagen, chondroitin sulfate, low-molecular weight hyaluronic acid, Pycnogenol®, and coenzyme Q10 significantly improved skin hydration, elasticity, nail hardness, and hair condition in patients with age-related dermatological changes after 12 weeks.